SciBac to present at the Biotech Showcase™ Annual Conference on January 10th
San Francisco, January 1, 2018 – SciBac today announced that it will present at Biotech Showcase ™ 2018, to be held January 8–10 during the most important week in healthcare at the Hilton San Francisco Union Square.
CEO Jeanette Mucha will present at the Biotech Showcase™ as follows:
Date: Wednesday, January 10, 2018
Time: 1:45 p.m. (PST)
Room: Franciscan - A (Ballroom Level)
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)
SciBac creates rEvolutionary live biotherapeutics that treat antibiotic resistant disease while fortifying the microbiome. They improve beneficial microorganisms using their patented DRIVE (Directed Recombination by In Vitro Evolution) platform technology that can quickly, naturally, and safely transfer useful genetic traits. The resulting microorganisms have all the best traits to target a specific disease through multiple modes of action and enhance the microbiome for faster recovery and reduced risk of reinfections. By focusing on developing therapies for antibiotic resistant diseases, SciBac fills a rapidly increasing medical need.
SciBac’s first product targets the nation’s biggest antibiotic resistant threat, Clostridium difficile infection. Their microorganism strains out compete C. difficile by stopping colonization, neutralizing toxins, and directly killing the C. difficile organism. Unlike antibiotics, their product only targets C. difficile, allowing the rest of a patient’s microbiome to thrive, speeding up patient recovery and lowering the risk of recurrence.
Biotech Showcase™, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.
Sara Demy-Colton, CEO of Demy-Colton, said: “We are delighted that SciBac will be presenting at Biotech Showcase this year. Biotech Showcase is the perfect platform for life science companies to showcase their innovation and seek out their next deal. This year again we are thrilled to be hosting what we believe will be the great business development opportunity of 2018.”
Jeanette Mucha, CEO of SciBac, said: “I am excited to present SciBac’s solutions for antibiotic resistant disease at Biotech Showcase this month. Fortuitously timed with our Series A raise and recent validation from public and private sectors.”
Founded in 2015, SciBac uses its patented DRIVE technology to create biotherapeutics that treat antibiotic resistant disease while fortifying the microbiome. SciBac’s biotherapeutics consist of hybrid microorganisms that are designed to have all the best traits to target a specific disease through multiple modes of action and enhance the microbiome for faster recovery and reduced risk of reinfections. For more information, visit www.scibac.com.
Additional links and information:
Follow Biotech Showcase on Twitter: @EBDGroup and @Demy_Colton - #BiotechShowcase